Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12467662 | 0.78 | PDPK1 (0.36) | PDPK1AURKATGFBR1ROCK1AURKB | |
| SCHEMBL14813996 | 0.77 | JAK2 (0.36) | PDPK1AURKATGFBR1ROCK1AURKB | |
| SCHEMBL14814040 | 0.70 | TYMS (0.34) | — | |
| SCHEMBL10333403 | 0.69 | PDE3B (0.51) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL22437180 | 0.69 | MAPT (0.38) | AURKAAURKBCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL7261096 | 0.68 | JAK2 (0.44) | PDPK1AURKATGFBR1ROCK1AURKB | |
| SCHEMBL14814033 | 0.68 | HPGD (0.36) | ALDH1A1HPGDSMN1; SMN2HSD17B10TSHR | |
| SCHEMBL28515421 | 0.67 | SIRT2 (0.46) | PDPK1AURKATGFBR1ROCK1AURKB | |
| SCHEMBL10333750 | 0.67 | PDE3B (0.54) | AURKACYP1A2CYP2C19ALDH1A1KDM4E | |
| SCHEMBL10333544 | 0.66 | PDE3B (0.57) | ALDH1A1KDM4EHPGDHSD17B10NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668184-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PF MEDICAMENT (FR) | 2018-01-10 | — | — | EP | disclosed |
| EP-2877176-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PF MEDICAMENT (FR) | 2017-04-26 | — | — | EP | disclosed |
| EP-2877177-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PF MEDICAMENT (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9428510-B2 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk | PIERRE FABRE MEDICAMENT (FR) | 2016-08-30 | — | — | US | disclosed |
| US-9381195-B2 | Derivatives of azaindazole or diazaindazole type for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2016-07-05 | — | — | US | disclosed |
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | PIERRE FABRE MEDICAMENT (FR) | 2015-09-24 | — | — | US | disclosed |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2015-07-09 | — | — | US | disclosed |
| EP-2877177-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | Pierre Fabre Médicament (FR) | 2015-06-03 | — | — | EP | disclosed |
| EP-2877176-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | Pierre Fabre Médicament (FR) | 2015-06-03 | — | — | EP | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| WO-2014016434-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| WO-2014016433-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2014-01-30 | — | — | WO | disclosed |
| EP-2689778-A1 | Derivatives of azaindoles or diazaindoles for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2689779-A1 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2668184-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | Pierre Fabre Medicament (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
| WO-2012101239-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | TTK, NTRK1, NTRK3 | PDPK1 443/4885AURKA 138/4885TGFBR1 2105/4885 |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | PDPK1 175/4885AURKA 145/4885TGFBR1 2037/4885 |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | SCN3A, ACHE, QDPR | PDPK1 2660/4885AURKA 1407/4885TGFBR1 4205/4885 |
| US-20130172360-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | PDPK1 175/4885AURKA 145/4885TGFBR1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.